U.S.-listed companies 5 companies face class actions, including SES and GOSS
Several law firms have filed class actions against U.S.-listed companies 5 companies. The lawsuits include a range of allegations, including false or exaggerated disclosures, inflated revenue, concealed clinical trials, project fraud, and underestimation of competition.
Several law firms have filed class actions against several U.S.-listed companies. The companies named are SES AI (SES), Regencell (RGC), Gossamer Bio (GOSS), New Era Energy (NUAI), and AeroVironment (AVAV). The lawsuits mainly concern allegations of false and exaggerated disclosures.
The lawsuit against SES AI includes allegations that it exaggerated its trading performance and generated artificial revenue through circular trading. The lawsuit covers investors who purchased shares between 2025 of 1 and 29 and 2026 of 3 and 4. The allegations also take issue with the concealment of logistics constraints.
The lawsuit documents also state that SES AI’s share price fell 36.8% to 1.08 dollars immediately after the announcement. The documents say that this change caused investor losses. The law firm is advising investors who suffered losses to apply to serve as lead plaintiffs.
The lawsuit against Regencell includes allegations that the company concealed its vulnerability to market manipulation, stock-price volatility, and regulatory exposure. The lawsuit covers investors who purchased shares from 2024 in 10 of 28 to 2025 in 10 of 31. The allegations are based on investor losses.
The Gossamer Bio lawsuit alleges that the company concealed placebo-response problems in its pulmonary arterial hypertension treatment’s Phase 3 trial. The lawsuit covers investors who purchased shares from 2025 in 6 of 16 to 2026 in 2 of 20. The documents stated that control of placebo responses at trial sites in Latin America was an issue.
The New Era Energy lawsuit alleges false statements concerning a Texas data center project and fraud related to an oil field in New Mexico. The lawsuit covers investors who purchased shares from 2024 in 11 of 6 to 2025 in 12 of 29. The law firm is urging investors to seek lead-plaintiff status based on their investment losses.
The lawsuit against AeroVironment alleges that the company understated competition for the SCAR program contract and competition related to U.S. Space Force modernization. The lawsuit covers investors who purchased shares from 2025 in 6 of 25 to 2026 in 3 of 10. The lawsuit documents identified the legitimacy of future contract prospects as an issue.
Sources: GlobeNewswire Inc.,Benzinga
Bullstory synthesized this report from the linked sources. AI may have assisted the writing process. Check the original reports for factual confirmation.